US biologicals has launched SARS-CoV-2 Nucleocapsid Antibody Pair


US biologicals has launched SARS-CoV-2 Nucleocapsid Antibody Pair



Our renowed Principal US biologicals has launched SARS-CoV-2 Nucleocapsid antibody pair which is capable of detecting the conserved nucleoprotein domain of SARS-CoV-2 variants of interest including Omicron (B.1.1.529) in various commercially available COVID-19 rapid antigen tests. SARS-CoV-2 is a respiratory virus which causes coronavirus disease 2019 (COVID-19). This disease spreads primarily through contact with an infected person via respiratory droplets generated when a person coughs or sneezes, or through droplets of saliva or discharge from the nose. Infection with SARS-CoV-2 can cause mild symptoms including a runny nose, sore throat, cough, and fever. However, it can be more severe for some people and can lead to pneumonia or breathing difficulties. The elderly, and people with pre-existing medical conditions (such as, diabetes and heart disease) appear to be more vulnerable to becoming severely ill with the virus. This pair recognizes the SARS-CoV-2 Nucleocapsid and does not cross react with any other coronavirus except SARS (2003). It is also capable of detecting the conserved nucleoprotein domain of SARS-CoV-2 variants of interest including Omicron (B.1.1.529) in various commercially available COVID-19 rapid antigen tests.